Tumor Necrosis Factor Receptor Superfamily Member 18 stages of development 2019

Posted on 2019-10-01 by Mark Hub in Pharmaceuticals // 0 Comments

Albany, US, 2019-Oct-01 — /EPR Network/ —The global market status for Tumor Necrosis Factor Receptor Superfamily Member 18 is precisely examined through a smart research report added to the broad database managed by Market Research Hub (MRH). This study is titled “Tumor Necrosis Factor Receptor Superfamily Member 18-Pipeline Review, H2 2019”, which tends to deliver in-depth knowledge associated to the Tumor Necrosis Factor Receptor Superfamily Member 18 for the present and forecasted period until 2019. Furthermore, the report examines the target market based on market size, revenue and geography; making it quite useful for the readers.

Get Sample Copy at https://www.marketresearchhub.com/enquiry.php?type=S&repid=2519489

Tumor Necrosis Factor Receptor Superfamily Member 18 – Pipeline Review, H2 2019

Summary

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) pipeline Target constitutes close to 15 molecules. The latest report Tumor Necrosis Factor Receptor Superfamily Member 18 – Pipeline Review, H2 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) – Glucocorticoid induced tumor necrosis factor receptor or TNFRSF18 or AITR is a protein encoded by TNFRSF18 gene. TNFSF18 is involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. It mediated NF-kappa-B activation via the TRAF2/NIK pathway. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 5 and 3 respectively.

Report covers products from therapy areas Oncology which include indications Solid Tumor, Melanoma, Non-Small Cell Lung Cancer, Hematological Tumor, Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Adenocarcinoma Of The Gastroesophageal Junction, Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Colorectal Tumor, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Fallopian Tube Cancer, Gastric Cancer, Hepatocellular Carcinoma, Lymphoma, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Ocular Melanoma, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer and Renal Cell Carcinoma.

Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

– The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18)
– The report reviews Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics and enlists all their major and minor projects
– The report assesses Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics

Browse Complete Report at https://www.marketresearchhub.com/report/tumor-necrosis-factor-receptor-superfamily-member-18-pipeline-review-h2-2019-report.html

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) – Overview
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) – Companies Involved in Therapeutics Development
Abeome Corp
Ablynx NV
Alligator Bioscience AB
Apogenix AG
Bristol-Myers Squibb Co
Checkpoint Therapeutics Inc
GigaGen Inc
IGM Biosciences Inc
Incyte Corp
Leap Therapeutics Inc
Merck & Co Inc
Novartis AG
Regeneron Pharmaceuticals Inc
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) – Drug Profiles
ABM-410 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATOR-1144 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986156 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CK-302 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Agonize GITR for Solid Tumor and Hematological Tumor – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GWN-323 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCAGN-1876 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-1248 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-4166 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Agonize GITR for Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Agonize GITR for Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Agonize GITR for Hematological Tumor and Solid Tumor – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Agonize GITR for Solid Tumors – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PTZ-522 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRX-518 – Drug Profile
Product Description

Make An Enquiry About This Report https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=2519489

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like Pharmaceuticals market research and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick